Señales en vivo de EDSA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	3 490.00
Volumen promedio	11 753.00
Capitalización de mercado	14.69M
EPS	$-0.600 ( 2024-02-09 )
Próxima fecha de ganancias	( $-0.690 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0.101 (2.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Nijhawan Pardeep	Buy	3 083	Common Share
2024-04-01	Nijhawan Pardeep	Buy	3 253	Common Shares
2024-03-25	Nijhawan Pardeep	Buy	5 000	Common Shares
2024-03-01	Nijhawan Pardeep	Buy	2 765	Common Shares
2024-02-01	Nijhawan Pardeep	Buy	2 978	Common Shares

INSIDER POWER
76.45
Last 96 transactions
Buy: 2 359 109 \| Sell: 304 857

Edesa Biotech Inc Correlación

10 Correlaciones Más Positivas
CTRM	0.95
FSEA	0.947
INPX	0.946
SSBK	0.943
XOS	0.941
NUWE	0.937
SBFG	0.935
FFWM	0.934
SGMO	0.934
MDRX	0.933

10 Correlaciones Más Negativas
RMRM	-0.927
MCAA	-0.925
QQC	-0.925
PLPC	-0.92
BNIX	-0.92
MSDA	-0.915
DSEY	-0.913
ZING	-0.912
ARNA	-0.912
VMGA	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Edesa Biotech Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-183 471 (0.00 %)
EPS:	$-0.420

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-183 471 (0.00 %)
EPS:	$-0.420

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-118 188 (0.00 %)
EPS:	$-1.050

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Edesa Biotech Inc

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Actualizaciones en tiempo real para Edesa Biotech Inc [EDSA]

Upcoming Earnings Alert